Request Trial
9 November 2026NewsIn-house counselMarisa Woutersen

How in-house teams can get more value from external counsel

From deciding what to outsource to managing legal fees and foreign counsel relationships, panellists at LSPN Fall, from Addition Therapeutics, Arcus Biosciences and the Law Office of Athena Zhou, shared practical advice for making IP budgets go further.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

In-house counsel
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
4 November 2026   AI agents are no longer just helping patent lawyers with their workload. Some are now doing the work themselves. In-house counsel from Insitro, Illumina, 10x Genomics and Invenra discuss how much can be handed over and whether humans could be replaced.
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026   With budgets under pressure, counsel from Pfizer, ALX Oncology and BioMarin share how they are reassessing portfolios, trimming costs and prioritising key markets at LSPN Fall.
In-house counsel
‘Companies that don’t leverage AI will struggle to keep up’: Umicore IP chief
26 October 2026   Umicore’s Sean Alexander has seen the profession change considerably over three decades, but some of its biggest changes may still lie ahead. He tells LSIPR why AI is prompting difficult decisions, what he is no longer willing to pay external counsel for and why Europe is the place to watch.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

Settled expectations, the six-year rule, and developments in USPTO policy
Regulatory and patent teams must align, say Amgen, Genentech, ORIC
EPO starts using AI for minutes but no access to transcripts for parties
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
Dykema’s new trademark pro will be a ‘tremendous asset’ to clients
In-house counsel rethink patent filing strategies as costs mount
Fenwick hires NY partner to advise on regulatory matters
UK unveils £1bn sector investment push after recent setbacks